By Ian Walker 
 

GlaxoSmithKline PLC's (GSK.LN) joint-venture company ViiV Healthcare said Thursday that a global phase 3 "Atlas-2M" study of rilpivirine for the treatment of HIV met its primary endpoint.

ViiV Healthcare--which is jointly owned by Pfizer Inc. (PFE)--said the study showed a combination of cabotegravir and rilpivirine administered every eight weeks is similar to a four-week administration.

"The Atlas-2M study results mean that people living with HIV could maintain viral suppression with six total treatments per year, instead of a daily oral treatment 365 times per year," Viiv Healthcare's Head of Research & Development Kimberly Smith said.

 

Write to Ian Walker at ian.walker@wsj.com

 

(END) Dow Jones Newswires

August 22, 2019 02:55 ET (06:55 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Pfizer Charts.